Compugen (CGEN) Aktsia Kursus

Compugen Ltd is primarily active in the biotechnology industry.

Compugen Ltd faces competition from various players in the market. Some of the main competitors of Compugen Ltd include industry giants like Gilead Sciences, Inc., Johnson & Johnson, and Bristol-Myers Squibb Company. These companies, along with others in the pharmaceutical and biotechnology sectors, pose a significant challenge to Compugen Ltd's market presence. However, Compugen Ltd's unique portfolio and innovative approach towards drug discovery and development help differentiate it from competitors and provide a competitive edge.

Compugen Ltd is a renowned biotechnology company based in Israel. Founded in 1993, the company specializes in predictive drug discovery and development using its proprietary computational technologies. With a focus on immuno-oncology, Compugen aims to harness the immune system's power to fight cancer effectively. Over the years, Compugen has established collaborations with leading pharmaceutical and biotech companies to accelerate its drug development programs. They have also generated a robust pipeline of novel, immune checkpoint targets for potential therapeutic interventions. With its innovative approach and strong expertise, Compugen Ltd strives to revolutionize cancer treatment and improve patient outcomes.

Compugen Ltd has achieved numerous significant milestones throughout its history. Some notable accomplishments include the discovery and validation of over 2,300 potential therapeutic targets, the development of innovative platforms for drug discovery, and the establishment of strategic partnerships with leading pharmaceutical companies. Additionally, Compugen Ltd has made advancements in the field of immuno-oncology, with the successful preclinical demonstrations of several novel immune checkpoint targets. These achievements showcase the company's commitment to pioneering research, collaboration, and progress in biotechnology. Compugen Ltd continues to strive towards revolutionizing the development of novel therapeutics for various diseases and solidifying its position as a key player in the industry.

Compugen Ltd is primarily present in the United States, Israel, and Canada.

Compugen Ltd represents values of innovation, collaboration, and scientific excellence. As a leading biotechnology company, they strive to discover and develop novel therapeutic solutions to address unmet medical needs. Their corporate philosophy is centered around harnessing the power of artificial intelligence and deep learning algorithms to enable predictive identification and validation of drug targets. By leveraging their proprietary computational platforms, Compugen Ltd aims to revolutionize the field of immunology and oncology, ultimately improving patient outcomes. Through their commitment to pioneering research and strong partnerships, Compugen Ltd is dedicated to delivering innovative and effective treatments for complex diseases.

Analüütikud määravad Compugen aktsiale keskmiseks hinnasihi 5,00 USD (mediaan: 5,00 USD), mis on +152,5 % viimase hinna suhtes. Konsensus põhineb 11 analüütiku hinnangul.

Compugen Analüütikute kurssizihtpunktid 2026

11 analüütikut hindavad praegu Compugen aktsiat: 10 soovitab osta, 1 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Compugen teenib tulu 10,20 M USD ja kasumit aktsia kohta −0,28 USD.

Compugen Analüütikute kurssizihtpunktid 2026

Praeguse kursiga kaubeldakse Compugen aktsiaga 1,77 EUR (1,98 USD) juures.

Compugen aktsia (CGEN) on noteeritud 5 börsil, sh: NASDAQ (CGEN), Frankfurt (CW9.F), Stuttgart (CW9.SG), Berlin (CW9.BE).

Compugen Ltd. is a leading company in the development and marketing of computer-based solutions for biology and medicine. The company utilizes its extensive expertise in the field of bioinformatics to develop innovative software and data analysis tools that are applied in pharmacy, oncology therapies, and diagnostics. The business model of Compugen comprises several divisions. The first one involves the identification of target molecules that can be used for medical purposes. The company utilizes its ability to investigate complex biological data and extract relevant information from the analysis. The resulting insights are used to determine new targets for drug development. Another division of Compugen is drug development. The company focuses on the discovery of novel therapeutic targets and their implementation into successful and efficient medications. Compugen employs state-of-the-art technologies and methods such as immunomodulation and inhibition of tumor growth. Furthermore, the company also has its own diagnostic platform. This platform aims to assist doctors and patients in making more targeted diagnoses and selecting appropriate therapies. Compugen relies on its expertise in the analysis of biomarkers and diagnostic biomolecules. Another area of activity for the company is the development of software products. Compugen offers its customers software tools tailored to specific needs, which support the analysis of biological data and the development of new medications. Overall, the business model of Compugen is characterized by a high focus on innovation and research. The company aims to support its customers in the development of new diagnosis and treatment possibilities based on modern and data-driven bioinformatics. With its products and services, Compugen targets a wide range of applications. From pharmacy to precision medicine and diagnostics, the company offers diverse solutions to its customers. It can draw on a successful history of development partnerships and strategic alliances, which have provided it with important positions and a global presence. In summary, the business model of Compugen Ltd. is shaped by its expertise in bioinformatics, a high willingness to innovate, and close collaboration with customers and partners. Through its various divisions, it offers a broad range of products targeting different application areas and emphasizing high quality and scientific competence.

oodatav Compugen käive on 10,20 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.

oodatav Compugen kasum on −26,27 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.

Võrdlusarvud hinna ja kasumiga (P/E) Compugen jaoks on praegu −7,14. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Compugen aktsia väärtust.

Kursuse ja müügimahu suhe (P/S) Compugen jaoks on praegu 18,39. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Compugen aktsia jaoks.

Eulpooli kvaliteedinäitaja Compugen jaoks on 7/10.

Compugen ISIN on IL0010852080. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Compugen WKN on 553001. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

Compugen ticker on CGEN. Ticker-sümbol kasutatakse Compugen aktsiate kauplemiseks börsil.